Theophylline for the treatment of bronchial asthma: Present status

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 22, Issue 5, 2000, Pages 309-320

  Kawai, M ^a   Kato, M ^a  

^a Kyoto Preventive Medical Center   (Japan)

Author keywords

Adverse effects; Aminophylline; Drug interaction; Pharmacology; Theophylline

Indexed keywords

ALLOPURINOL; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CEFACLOR; CIMETIDINE; CIPROFLOXACIN; CORTICOSTEROID; ERYTHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MACROLIDE; METOPROLOL; MEXILETINE; MIDECAMYCIN; NIFEDIPINE; PROBENECID; QUINOLONE; RANITIDINE; RIFAMPICIN; STEROID; TETRACYCLINE; THEOBROMINE; THEOPHYLLINE; TICLOPIDINE; UNINDEXED DRUG; XANTHINE DEHYDROGENASE; XANTHINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; IMMUNOMODULATION; INFECTION; JAPAN; LIVER DISEASE; PRACTICE GUIDELINE; REVIEW; THEOPHYLLINE BLOOD LEVEL; THYROID DISEASE;

EID: 0033839352     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2000.22.5.796650     Document Type: Review

References (199)

1. On some points in the treatment clinical history of asthma
2. Successful treatment of persistent extreme dyspnea 'status asthmaticus': Use of theophylline ethylenediamine (aminophylline, U.S. P.) intravenously
3. Aminophylline toxicity
4. Clinical pharmacokinetics of theophylline
5. Monitoring serum theophylline levels
6. Evaluation of oral bronchodilator therapy in asthmatic children
7. Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study
8. The value of maintenance theophylline in steroid-dependent asthma
9. Comparison of orally administered metaproterenol and theopbylline in the control of chronic asthma
10. A clinical pharmacokinetic basis for the selection and use of slow release theophylline products
11. Some pharmacological aspects on xanthines in asthma
12. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction
13. Aminophylline improves diaphragmatic contractility
14. Extrapulmonary effects of theophylline
15. PDE isoenzymes as targets for anti-asthma drugs
16. Prevention of apnea and bradycardia in low-birthweight infants
17. Metabolic responses to plasma concentrations of theophylline
18. Increase in plasma free fatty acids and natriuresis by xanthines may reflect adenosine antagonism
19. Theophylline increases serum uric acid levels
20. Reduction of liver plasma flow by caffeine and theophylline
21. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline
22. Dipyridamole-is it a bronchodilator?
23. Methylxanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation
24. Apparent irrelevance of cyclic nucleotides to the relaxation of tracheal smooth muscle induced by theophylline
25. Effect of theophylline on the binding of cAMP to soluble protein from tracheal smooth muscles
26. Theophylline actions on adenosine receptors
27. Subclasses of external adenosine receptors
28. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects
29. Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline
30. Xanthines for asthma-present status
31. Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease
32. Adenosine antagonism, a less desirable characteristic of xanthine asthma drugs?
33. Stimudation of endogenous catecholamine release by theophylline: A proposed additional mechanism of action for theophylline effects
34. Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man
35. The effect of posture on the sympathoadrenal response to theophylline infusion
36. Failure of chronic theophylline therapy to alter circulating catecholamines
37. Theophylline as an anti-inflammatory agent
38. Rational intravenous doses of theophylline
39. Pharmacokinetics of theophylline, application to adjustment of the clinical dose of aminophylline
40. Pharmacologic effects of intravenously administered aminophylline in asthmatic children
41. Relationship of serum theophylline concentration to inhibition of exercise-induced bronchospasm and comparison with cromolyn
42. Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children
43. Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: The optimal use of intravenously administered aminophylline
44. Theophylline-induced seizures in adults, correlation with serum concentration
45. Dosage of theophylline in bronchial asthma
46. Clinical experience with theophylline: Relationships between dosage, serum concentration, and toxicity
47. Grand mal seizure induced by oral theophylline
48. Frequent toxicity from iv aminophylline infusions in critically ill patients
49. Theophylline concentrations in asthmatic patients after administration of aminophylline
50. Theophylline poisoning in adults
51. Oral sustained-release aminophylline in medical inpatients: Factors related to toxicity and plasma theophylline concentrations
52. Metabolism of theophylline to caffeine in premature newborn infants
53. Theophylline metabolism in premature infants
54. Theophylline metabolism during first month of life and development
55. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant
56. Comparative efficacy of theophylline and caffeine in the treament of idiopathic apnea in premature infants
57. Disposition of theophylline after a single intravenous infusion of aminophylline
58. Avoidance of adverse effects during chronic therapy with theophylline
59. Rapidly achieved plasma concentration plateaus, with observations on theophylline kinetics
60. Pharmacokinetics of intravenous theophylline
61. Intravenous aminophylline dosage: Use of serum theophylline measurement for guidance
62. Relationship of theophylline clearance to oral dosage in children with chronic asthma
63. Absolute bioavailability of oral theophylline
64. Theophylline bioavailability, a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline
65. Disposition and clinical pharmacokinetics of microcrystalline theophylline
66. Bioavailability and pharmcokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. A single dose study
67. The relation of product formulation to absorption of oral theophylline
68. Theophylline bioavailability following oral administration of six sustained-release preparations
69. Evaluation of the absorption from some commercial sustained-release theophylline products
70. Absorption of sustained-release theophylline tablets
71. Relationship between theophylline concentration in plasma and saliva of man
72. Pharmacokinetic aspects of theophylline in premature newborns
73. Theophylline secretion into breast milk
74. Theophylline serum protein binding in obstructive airways disease
75. Factors influencing theophylline serum protein binding
76. Binding of theophylline in human serum determined by ultrafiltration and equilibrium dialysis
77. Determinants of the plasma protein binding of theophylline in health
78. Comparison of methods for determining unbound theophylline concentrations
79. Placental transfer of theophylline: Two case reports
80. Monitoring children on sustained-release therapy by salivary theophylline levels
81. Kinetics of theophylline transfer to breast milk
82. Caffeine and theophylline: Serum/CSF correlation in premature infants
83. The relationship of cerebrospinal fluid and plasma theophylline concentrations in children and adolescents taking theophylline
84. Theophylline disposition in patients with hepatic cirrhosis
85. Pharmacokinetics of theophylline in hepatic disease
86. Theophylline pharmaco-kinetics in premature infants with apnea
87. Theophylline disposition in obesity
88. Volume of distribution of theophylline in acute exacerbation of reversible airway disease. Effect of body weight
89. Influence of body fat on the volume of distribution of theophylline
90. A study of the metabolism of theobromine, theophylline, and caffeine in man
91. Effects of allopurinol on theophylline metabolism and clearance
92. Measurement of excretion characteristics of theophylline and its major metabolites
93. Nonlinear theophylline elimination
94. Non-linear elimination processes of theophylline
95. The effect of acute and chronic renal failure on theophylline clearance
96. Secondary metabolism of theophylline biotransformation products in man-route of formation of 1-methyluric acid
97. A practical guide to interactions involving theophylline kinetics
98. Theophylline reassessed
99. Pharmacokinetic drug interactions with theophylline
100. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children
101. Oral aminophylline therapy: Increased dosage requirements in children
102. Pharmacokinetics of theophylline in children with asthma
103. The relationship between clearance of theophylline and age within the adult age range
104. Individualized aminophylline therapy in patients with obstructive airway disease: Oral dosage prediction from an intravenous test dose
105. Influence of age on theophylline clearance in patients with chronic obstructive pulmonary disease
106. Theophylline kinetics in relation to age: The importance of smoking
107. Theophylline pharmacokinetics in advanced age
108. Theophylline kinetics in chronic obstructive airway disease in the elderly
109. Enhanced biotrans-formation of theophylline in marihuana and tobacco smokers
110. Decreased theophylline half-life in cigarette smokers
111. Effect of smoking on theophylline disposition
112. Cigarette smoking and theophylline clearance and metabolism
113. Factors affecting theophylline clearance: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol
114. Theophylline disposition in acutely ill hospitalized patients: The effect of smoking, heart failure, severe airway obstruction, and pneumonia
115. Theophylline kinetics in acute pulmonary edema
116. Changes in theophylline clearance during acute, illness
117. Apparent theophylline half-life fluctuations during treatment of acute left ventricular failure
118. Life-threatening theophylline intoxication in a hypothyroid patient
119. Increased theophylline clearance in a patient with hyperthyroidism
120. Influence of thyroid function on theophylline kinetics
121. Altered theophylline pharmacokinetics during acute respiratory viral illness
122. Vaccine-drug interactions
123. Effects of influenza virus vaccine on hepatic drug metabolism
124. Intrapatient variability in theophylline kinetics
125. Intraindividual changes in theophylline clearance during constant aminophylline infusion in children with acute asthma
126. A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission
127. Kinetics of theophylline variability and effect of arterial pH in chronic obstructive lung disease
128. Theophylline binding to plasma proteins in patients with chronic obstructive pulmonary disease
129. The relationship between arterial blood gases and serum theophylline clearance in critically ill patients
130. Theophylline clearante in patients with severe chronic obstructive pulmonary disease receiving supplemental oxygen and the effect of acute hypoxemia
131. Acute asthma and antidiuretic hormone secretion
132. Effect of phenobarbital on the disposition of intravenous theophylline
133. Effect of phenobarbital on theophylline disposition
134. The effect of phenobarbital on theophylline disposition in children with asthma
135. Phenytoin-theophylline interaction
136. Influence of phenytoin on theophylline clearance
137. Reduced theophylline half-life induced by carbamazepine therapy
138. Alteration of theophylline clearance and half-life by cimetidine in normal volunteers
139. Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: A study using stable isotope methodology during multiple oral dose administration
140. Cimetidine-theophylline interaction: Effects of age and cimetidine dose
141. Inhibition theophylline clearance by cimetidine but not ranitidine
142. Differential effects of cimetidine on theophylline metabolic pathways
143. Cigarette smoking and theophylline metabolism: Effects of cimetidine
144. Effects of cimetidine and ranitidine on hepatic drug metabolism
145. Ranitidine at very large doses does not inhibit theophylline elimination
146. Inhibition of theophylline clearance by troleandomycin
147. Effects of three antibiotics on theophylline kinetics
148. The effects of erythromycin on the absorption and disposition kinetics of theophylline
149. The effect of erythromycin on theophylline pharmacokinetics at steady state
150. Effect of erythromycin on theophylline kinetics
151. Depression of theophylline elimination by erythromycin
152. The effects of erythromycin on theophylline elimination in normal males
153. Pharmacokinetic interaction between theophylline and erythromycin
154. The interaction of erythromycin with theophylline
155. Spiramycin has no effect on serum theophylline in asthmatic patients
156. Effect of miocamycin on theophylline kinetics in children
157. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450
158. Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450, comparison with troleandomycin
159. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats
160. The effect of rifampin on theophylline disposition
161. Theophylliner4ifampicin interaction: Non-selective induction of theophylline metabolic pathways
162. Effect of rifampicin administration on theophylline pharmacokinetics in humans
163. The effect of rifampin on theophylline kinetics
164. Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease
165. No influence of doxycycline on theophylline pharmacokinetics
166. Lack of effect of amoxicillin on theophylline pharmacokinetics
167. No effect of cefaclor on theophylline pharmacokinetics
168. Impact of cefaclor on the pharmacokinetics of theophylline
169. Isoniazid-induced alterations in theophylline pharmacokinetics
170. Interaction between isoniazid and theophylline
171. Lack of influence of co-trimoxazole on theophylline pharmacokinetics
172. Lack of inhibitory effect of metronidazole on theophylline disposition in healthy subjects
173. Effect of ketoconazole on hepatic oxidative drug metabolism
174. Enoxacin decreases the clearance of theophylline in man
175. The influence of quinolone derivatives on theophylline clearance
176. Pharmacokinetics of ofloxacin and theophylline alone and in combination
177. Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration
178. Orciprenaline does not alter theophylline elimination
179. Effect of intravenous isoproterenol on theophylline kinetics
180. Reduction of serum theophylline levels by terbutaline in children with asthma
181. Effects of metoprolol and propranolol on theophylline elimination
182. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man
183. Asthma-a possible interaction between hydrocortisone and theophylline
184. The effect of corticosteroids on theophylline metabolism
185. Effects of betamethasone on theophylline disposition in man. Are saliva values predictive of serum theophylline levels?
186. Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction
187. Influence of medroxyprogesterone on theophylline disposition
188. Mechanism of interaction between theophylline and mexiletine
189. Influence of allopurinol on theophylline disposition in adults
190. Inhibition of theophylline metabolism by long-term allopurinol administration
191. Ticlopidine-theophylline interaction
192. The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers
193. Effects of metoclopramide on the pharmacokinetics of a slow-release theophylline product
194. Effect of probenecid on the pharmaco-kinetics of aminophylline
195. Pirenzepine dose not alter the pharmacokinetics of theophylline
196. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man
197. Effect of dietary protein and carbohydrate on theophylline metabolism in children
198. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism
199. Influence of methylxanthine-containing foods on theophylline metabolism and kinetics